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Take-home message: Digital adherence technologies (DATs) provide a wealth of information 35 
on dose-by-dose anti-TB medication-taking. Studies of DAT data should place non-36 
adherence in standardised taxonomic frameworks in order to best inform intervention and 37 
regimen design. 38 
  39 
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Abstract 1 
Adherence to treatment for tuberculosis (TB) has been a concern for many decades, 2 
resulting in the World Health Organization’s recommendation of the direct observation of 3 
treatment in the 1990s. Recent advances in digital adherence technologies (DATs) have 4 
renewed discussion on how to best address non-adherence, as well as offering important 5 
information on dose-by-dose adherence patterns and their variability between countries and 6 
settings. Previous studies have largely focussed on percentage thresholds to delineate 7 
sufficient adherence, but this is misleading and limited, given the complex and dynamic 8 
nature of adherence over the treatment course. Instead, we apply a standardised taxonomy- 9 
as adopted by the international adherence community- to dose-by-dose medication-taking 10 
data, which divides missed doses into a) late/non-initiation (starting treatment later than 11 
expected/not starting), b) discontinuation (ending treatment early), and c) suboptimal 12 
implementation (intermittent missed doses). Using this taxonomy, we can consider the 13 
implications of different forms of non-adherence for intervention and regimen design. For 14 
example, can treatment regimens be adapted to increase the ‘forgiveness’ of common 15 
patterns of suboptimal implementation to protect against treatment failure and the 16 
development of drug resistance? Is it reasonable to treat all missed doses of treatment as 17 
equally problematic and equally common when deploying DATs? Can DAT data be used to 18 
indicate the patients that need enhanced levels of support during their treatment course? 19 
Critically, we pinpoint key areas where knowledge regarding treatment adherence is sparse 20 
and impeding scientific progress. 21 
  22 
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Introduction 1 
Many decades after initial trials of antimicrobials for TB,[1] the standard treatment for drug 2 
sensitive disease remains lengthy at six months; regimens for drug resistant disease can last 3 
for two years.[2] Concerns about adherence to treatment over such long periods - and the 4 
implications of that non-adherence - led to the World Health Organization (WHO) 5 
recommendation of directly observed treatment (DOT) in 1994.[3, 4]  6 
 7 
In recent years, digital adherence technologies (DATs; including SMS-based reminders, 8 
video supported therapy [VOT], and medication monitor boxes) have increasingly been 9 
tested as remote alternatives to DOT/other standards of care as they may be cheaper, more 10 
acceptable, and less financially and temporally burdensome.[5, 6] DATs provide healthcare 11 
workers with regular, up-to-date, information on how medication has been taken (either 12 
accessed at each appointment or remotely each day). DATs can be provided in different 13 
ways, e.g. to all patients as the sole source of support or as part of a package of 14 
interventions that is personalised to an individual’s needs.[7] Intervention packages may be 15 
reviewed as a result of appointment-by-appointment (or remote dose-by-dose) evaluation of 16 
DAT data that demonstrates the need for enhanced treatment support.[8, 9] Such reviews 17 
could also help to determine the patients least in need of dose-by-dose monitoring i.e. 18 
providing a ‘step-down’ approach during treatment. 19 
 20 
Like DOT, DATs are interventions to promote dose-taking that assumes all doses are of 21 
equal importance. This one-size-fits-all approach latently assumes that missed doses are 22 
essentially interchangeable i.e. that each is of equal importance in terms of its clinical 23 
implications. This may not be the case; early stage adherence when bacterial loads are 24 
higher may be more important than late stage, for example. Additionally, it is assumed that 25 
DOT and DATs work equally well across the entire treatment period, which is not always the 26 
case.[10] 27 
 28 
The advent of DATs provides a unique moment to reassess our global approach to non-29 
adherence to anti-TB medications. Assuming that DAT event monitoring is equivalent to 30 
dose-taking, DAT devices provide rich digital datasets of date- and time-stamped information 31 
that have not previously been available to the research community. Key lessons about anti-32 
TB medication-taking and best practice for DAT deployment can be learnt, in order to avoid 33 
a simple duplication of our current global DOT approach and better personalise clinical care. 34 
 35 
In this paper, we take the opportunity of ongoing global evaluation and roll-out of DATs to 36 
review and refine a classification of non-adherence to treatment, examine the evidence for 37 
the global burden and association of different types of non-adherence with treatment 38 
outcomes, and consider what this refined classification of non-adherence means for 39 
intervention and regimen design and deployment. 40 
 41 
What is non-adherence? 42 
In this paper, we adopt a definition of adherence that emphasises the patient’s role in 43 
agreeing a treatment plan i.e.: 44 
Adherence- when a patient’s dose-taking, at any stage during treatment, matches 45 
mutually agreed recommendations from the prescriber.[11] 46 
Therefore, non-adherence represents a divergence from this agreement. 47 
 48 
Traditionally, TB research has assessed non-adherence using simple 80-90% thresholds of 49 
doses taken across the duration of treatment. To date, few studies have determined whether 50 
80-90% is the optimal point of inflection. Furthermore, this simple binary classification masks 51 
extensive complexity across the treatment period. Given this complexity, it is essential to lay 52 
out definitions and descriptors.[12, 13] In 2010, partly co-ordinated by the European Society 53 
for Patient Adherence, Compliance and Persistence (ESPACOMP), a new taxonomy for 54 
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non-adherence was launched.[14] This is the only globally accepted taxonomy for non-1 
adherence, which consists of three core concepts, which are mappable using dose-by-dose 2 
data, such as that provided by DATs (Figure 1a) and b)): 3 
1) Initiation, which tracks when the first dose of a regimen is taken relative to the 4 
intended start date. 5 
2) Discontinuation, which documents the cessation of treatment. 6 
3) Implementation- how doses are taken during the period of persistence (the 7 
timeframe between initiation and discontinuation) i.e. intermittent missed doses 8 
(treatment gaps). 9 
 10 
As a condition with a time-limited treatment period, TB lends itself to this definitions 11 
framework. Drug-sensitive TB is treated for six months with an all-oral regimen, starting with 12 
four drugs administered over two months (initiation phase; not to be confused with treatment 13 
initiation), followed by two drugs over four months (continuation phase).[15] It is usually 14 
dosed daily; in some places, thrice-weekly regimens (although problematic in their own right, 15 
see below) are utilised to allow to make DOT less burdensome on both the patient and the 16 
healthcare system. Fixed dose combination (FDC) pills are used in many settings. Thus the 17 
number of treatment doses expected to be taken in a week can vary from place to place and 18 
patient to patient; the number of pills this represents will also vary depending upon a 19 
patient’s weight. For drug-resistant TB, both regimens themselves and their dosing becomes 20 
more complex, and treatment more lengthy.[16]  21 
 22 
Within the context of non-adherence to TB treatment, the core concepts can be mapped as 23 
follows: 24 
1) Late initiation of, or not initiating, treatment: this charts the time frame between the 25 
intended treatment start date after a patient is informed of their diagnosis and the 26 
first dose being taken. The reasons for issues with initiation are multifactorial. 27 
Delays can be due to a lag in, or non-acquisition of, medication, as well as 28 
provided medication not being taken. Non-initiation may be driven by failures in 29 
the access of/linkage to care cascade with drivers and consequences that are, 30 
therefore, different from late initiation. 31 
2) Early discontinuation of treatment e.g. due to loss to follow-up (LFU; previously 32 
known as default).[17] 33 
3) Suboptimal implementation,[12] i.e. the form of non-adherence that has been the 34 
focus of both observational studies and clinical trials. 35 
 36 
 37 
Of note, LFU - as defined by the WHO[17] - is not a clear-cut proxy for early discontinuation 38 
of treatment. This is because it is both a standardised end-of-treatment outcome that is 39 
reported within surveillance systems (treatment is interrupted for two consecutive months or 40 
more), as well as occurring when a TB patient does not start treatment (‘initial LFU’ or ‘pre-41 
treatment LFU’).[18, 19] LFU thus a) contains some non-initiation and b) is not the only form 42 
of discontinuation due to the time constriction placed upon it. Furthermore, LFU documents 43 
non-engagement with clinical appointments, not medication-taking per se. 44 
 45 
In the next sections, we will discuss how the effect of the three core concepts of non-46 
adherence on TB control depends on two factors: 1) the prevalence of each kind of non-47 
adherence and 2) the impact of each type on treatment outcomes. Throughout this paper, 48 
we use a previously published dataset of DAT data to provide a worked example of the 49 
concepts that we illustrate (Table 1). 50 
 51 
  52 
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Late or non-initiation 1 
What is the global burden? 2 
Among our core components of non-adherence, non-initiation is arguably most on the global 3 
map, as a component part of the WHO’s campaign to find and treat the ‘missing millions’.[20] 4 
The precise number of patients not starting treatment is unknown, although WHO estimates 5 
treatment coverage to be 69% globally.[21] For rifampicin-resistant TB, Boyd et al. have 6 
estimated a similar global mean of 76% of individuals initiating treatment, among those 7 
diagnosed.[22] In a review of studies undertaken in low-income and lower-middle-income 8 
countries, or those with a high burden of TB, MacPherson et al. projected that 18% of 9 
individuals do not initiate treatment after diagnosis in African nations and 13% in Asian 10 
nations.[18] A later study estimated the figure to be 12% in South Africa.[19] 11 
 12 
A series of systematic reviews and meta-analyses have examined temporal delays in 13 
treatment initiation (the time frame between diagnosis and the start of treatment). In India 14 
among pulmonary TB patients, median delay was 2·5 days (IQR 1·9-3·6)[23] and in the 15 
Eastern Mediterranean Region zero to two days.[24] In comparison, a recent observational 16 
study from China found the median time from TB diagnosis to MDR TB treatment was six 17 
months.[25] This is because the situation in drug resistant disease is additionally complex, 18 
as patients may start on the six month regimen whilst waiting for drug sensitivity testing 19 
results before their treatment is adjusted (proving a window for further drug resistance to 20 
develop),[16] and sourcing second-line drugs may take time. 21 
 22 
What is the relationship with treatment outcomes? 23 
Examining the relationship between initiation of treatment and treatment outcomes is 24 
complicated by the different measures of lateness used in the literature. In many papers, an 25 
overall figure of the delay between symptoms and the start of treatment was quoted, rather 26 
than delays between diagnosis and the start of treatment (Figure 2). In sensu stricto, we 27 
sought to document delays between diagnosis (preferably when it was received by the 28 
patient) and the start of treatment only. 29 
 30 
In a 2018 review, Melsew et al. examined the impact of delays in starting treatment on 31 
patient infectiousness.[26] Among eight studies, four found evidence for an association 32 
between delays in treatment initiation after the onset of symptoms (with a roughly doubling of 33 
the odds of infectiousness), three found no evidence for an association, and one found 34 
mixed evidence. The delays charted were from less than a fortnight to more than 90 days. 35 
 36 
Evidence from Ethiopia documented a doubling in the adjusted relative risk of treatment 37 
failure, death or LFU among those for whom delay was >30 days.[27] This study used a 38 
measure of ‘overall delay’ (from the start of symptoms to the start of treatment) with a 39 
median of 55 days (inter-quartile range [IQR] 32-100) documented. Of this, 22 days (9-48) 40 
were classed as ‘provider delay’ i.e. the time post-presentation at a healthcare facility 41 
between diagnosis and the start of treatment. 42 
 43 
Among MDR patients in Myanmar, in a univariable analysis where treatment delay was 44 
classified as between the date of MDR-TB confirmation and the date of treatment initiation, 45 
the median treatment delay for patients with poor treatment outcomes (lost to follow up, 46 
failed, died) was 144 days, which was longer than among patients who achieved successful 47 
treatment outcomes (102 days).[28] In an adjusted analysis comparing the impact of long 48 
(≥median of 152 days) versus short (<median) delays, this association was not retained. 49 
 50 
In MDR TB patients in China results were also mixed, this time depending upon the measure 51 
of delay used. The time between TB diagnosis to the start of MDR treatment showed some 52 
effect, albeit with a null-inclusive confidence interval, whereas shorter delays (≤60 days) 53 
after the performance of DST showed a doubling or more in the likelihood of a positive 54 
treatment outcome, depending upon the other factors adjusted for.[25] 55 
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Discontinuation 1 
What is the global burden? 2 
Due to the substantial overlap with LFU and the use of this measure as a standardised 3 
reporting outcome, the estimates of the global burden of discontinuation have been captured 4 
in many studies. An individual patient data meta-analysis of 9,000 MDR TB patients from 23 5 
countries suggested around a sixth were lost to follow up, with a median timing of seven 6 
months.[29] In an older systematic review not specifically for drug-resistant disease, Kruk et 7 
al. documented likelihoods of LFU of 7-54% and timings of between 42 and 85 days in low- 8 
and middle-income settings.[30] There was large amounts of variation between countries 9 
and regions. Approaches that include a precise analysis of when discontinuation from 10 
treatment occurs and how this relates to LFU should become more common as dose-by-11 
dose monitoring systems are rolled out globally. 12 
 13 
What is the relationship with treatment outcomes? 14 
Determining the relationship between discontinuation and treatment outcomes is complex, 15 
given the use of LFU both as a marker of discontinuation and a negative surveillance 16 
outcome.[17] Useful sources of data include the randomised controlled trials (RCTs) that 17 
developed the standard regimen we use today. Historically, it was the addition of rifampicin 18 
and then pyrazinamide which allowed treatment to be shortened to six months;[31] further 19 
studies showed an important increase in the likelihood of post-treatment relapse when 20 
treatment was reduced to four months.[32] 21 
 22 
In recent years, several RCTs have sought to shorten the treatment of drug sensitive TB to 23 
four months by including fluoroquinolones, but, as yet, none have demonstrated non-24 
inferiority.[33-35] Pooled analyses have indicated that such regimens may be non-inferior in 25 
particular patient groups, indicating the need for stratified treatment approaches.[36] 26 
Although such regimens are intended to reduce non-adherence by shortening overall 27 
duration, this may increase the sensitivity of such regimens to suboptimal implementation i.e. 28 
the importance of each dose in the regimen may be increased, relative to a longer regimen, 29 
making each missed dose more problematic.  30 
 31 
Critically, well-designed studies using dose-by-dose monitoring systems such as DATs 32 
together with robust treatment outcome collection will go a long way towards answering 33 
remaining questions in this area. 34 
 35 
Suboptimal implementation 36 
What is the global burden? 37 
Until recently, suboptimal implementation for anti-TB treatment has been assessed through 38 
the differentially reliable self-reported or questionnaire-derived methods (for example [37, 39 
38]) and DOT (e.g. [10, 39-41]). Study protocols also used various thresholds to classify 40 
non-adherence, and often reported a mixture of suboptimal implementation and 41 
discontinuation in their analyses.  42 
 43 
To date, the burden of suboptimal implementation is suggested to be highly variable 44 
between countries and regions, e.g. 21·3% in pooled estimate from Ethiopia versus 90·8% in 45 
the Philippines, although differences will partly be protocol-dependent.[41, 42] Approaches 46 
that include a precise analysis of the types of suboptimal implementation displayed by 47 
patients should become more common as dose-by-dose monitoring systems are rolled out 48 
globally,[43] e.g. examining the lengths of gaps displayed and when they occur during 49 
treatment.[12, 44] For example, in a recent study in China, 47·2% of 780 patients had a 50 
dosing gap of a week or more and 95·9% some form of suboptimal implementation (Table 51 
1).[12]  52 
 53 
 54 
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What is the relationship with treatment outcomes? 1 
There has been substantial interest in the relationship between suboptimal implementation 2 
and various intermediate and final treatment outcomes. Largely using simple percentage 3 
adherence thresholds across the entire treatment period, suboptimal implementation has 4 
been associated with unsuccessful treatment outcomes in a variety of settings from Malawi 5 
to Israel, in both observational and randomised controlled trial datasets, and using a variety 6 
of methods to define and measure implementation.[36, 44-49] In observational datasets from 7 
Russia and the US, this association extends to the development of drug resistance,[50, 51] 8 
although in simulations it has not been consistently proven.[52] Recurrence of TB disease 9 
among pulmonary TB patients was higher with worse implementation in both the Yemen and 10 
Vietnam.[53, 54]  11 
 12 
Moving beyond adherence thresholds, in MDR TB patients in Armenia and Abkhazia on 13 
DOT, Bastard et al. noted the criticality of gap length and the time between gaps. Odds of 14 
negative outcomes (treatment failure, death or default) nearly quadrupled with interruptions 15 
of three or more days and also short periods (<10 days) between gaps.[44] From a different 16 
angle in drug-sensitive pulmonary TB, Johnston et al.’s meta-regression found that treatment 17 
failure, acquired drug resistance, and relapse were more common with thrice-weekly versus 18 
daily dosing.[55] The Imperial et al. pooled meta-analysis looked at the impact of a six days 19 
in seven versus a seven days in seven dosing strategy and found that the former increased 20 
the likelihood of an unfavourable outcome (broadly death, treatment failure, a lack of culture 21 
conversion, relapse, adverse events), as well as the implications of different adherence 22 
thresholds within this.[36] 23 
 24 
As for discontinuation, well-designed studies using DATs or other dose-by-dose monitoring 25 
systems will be essential to answer the remaining questions in this area. 26 
 27 
What do different types of non-adherence mean for intervention and regimen 28 
design and deployment? 29 
Effectively preventing non-adherence to treatment not only requires interventions 30 
appropriately tailored to patients and healthcare systems, but also the type of non-31 
adherence commonly displayed. Critically, the types of non-adherence displayed and their 32 
relationship to treatment outcomes may vary by population group e.g. people living with HIV, 33 
individuals with other comorbidities, children and the elderly. Elucidating these relationships 34 
requires setting-by-setting data collection using tools such as DATs. This should include how 35 
variability in adherence throughout treatment determines the need for ‘step-up’ interventions. 36 
 37 
Late or non-initiation 38 
Non-initiation of treatment after diagnosis can be due to a large number of complex factors, 39 
including the lack of accessibility of treatment - e.g. due to costs associated with attending 40 
the clinic; under-resourced or poorly functioning facilities; and stigma/lack of awareness of 41 
TB.[56-58] Here, interventions include broad systems-strengthening factors that will benefit 42 
the entire care cascade, such as better financing of healthcare systems; the provision of free 43 
TB drugs to everyone; and the removal of other financial barriers e.g. through cash transfer 44 
programmes,[59] as well as ‘pull factors’ such as improvement of the quality of care; 45 
increasing awareness of/decreasing stigma around TB; and improving case 46 
detection/outreach. Factors such as strengthening the care cascade and reducing stigma 47 
may reduce late initiation, too. 48 
 49 
Discontinuation 50 
If discontinuation occurs early enough, even if it is relatively uncommon, it can form a large 51 
proportion of missed doses during treatment (Figure 1c). As documented above, early 52 
discontinuation is also known to be highly detrimental to treatment outcomes. Therefore, 53 
settings should consider the relative burden of discontinuation versus other forms of non-54 
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adherence when planning for effective interventions to implement (Table 1). 1 
 2 
When it comes to intervention design, a single intervention may not address all 3 
discontinuation, as the drivers are not the same for every patient and sometimes reflect 4 
disengagement with care, rather than treatment. 5 
 6 
One of the key implications for the development of shorter treatment regimens is their 7 
potential to reduce discontinuation,[60] simply by reducing overall duration (Table 1). 8 
 9 
Suboptimal implementation and interventions 10 
Intelligent intervention design should be influenced by the common form of suboptimal 11 
implementation (including long versus short gaps and erratic versus regular missed doses; 12 
Figure 1d), their causes (i.e. treatment-related, individual knowledge and perceptions, social 13 
factors, systems issues, temporal factors, and structural factors.[61-64] Also influential, is 14 
whether non-adherence is intentional or unintentional,[11] however; making the distinction 15 
on an individual basis can be difficult and potentially fruitless. 16 
 17 
To date, many interventions have sought to target individual-level cognitive or behavioural 18 
factors such as forgetfulness or ‘misconceptions’ through SMS reminder systems, 19 
medication monitor box alarms, or the regular need to report for DOT or VOT.[43] More 20 
complex interventions are required to deal with multifactorial causes of non-adherence,[7] 21 
such as rapid reporting and support systems. As TB tends to affect socially and 22 
economically deprived groups, interventions that focus on individual agency and behaviour- 23 
but do not account for social and structural barriers to care (as well as factors that influence 24 
a patient’s ability to take medication regularly) - are destined to work primarily for those who 25 
already have better capacity and social circumstances.[65] 26 
 27 
Critically, adherence to treatment is dynamic and can change in response to events and life 28 
circumstances of all kinds over time,[66] producing ever-varying patterns of suboptimal 29 
implementation. Dose-by-dose monitoring systems that are accessible to healthcare 30 
services can be used to promote rapid responsiveness to the frequency and length of gaps 31 
that occur during treatment (Table 1), as part of the partnership between patients and 32 
healthcare providers.[67] 33 
 34 
Polypharmacy is of substantial concern as a cause of non-adherence,[68] and therefore 35 
population groups for whom this is an issue should have special consideration in intervention 36 
design. 37 
 38 
Suboptimal implementation and regimen forgiveness 39 
The ‘forgiveness’ of treatment regimens reflects their ability to withstand unexpected gaps in 40 
dosing.[69] Forgiveness varies from drug to drug, depending on pharmacokinetic 41 
parameters, thus each drug will respond individually to different patterns of suboptimal 42 
implementation. The development of drug resistance is a key consideration; differing gap 43 
lengths can lead to divergent results. Within multidrug regimens, such as those used for TB, 44 
the maintenance of sufficient drug blood levels to achieve an antibacterial effect depends 45 
upon the metabolism of all the component drugs and thus how they behave in combination. 46 
Dosing strategies may potentially be alterable to overcome non-forgiveness, but this should 47 
be undertaken in light of considerations surrounding the patient’s medication-taking burden 48 
(e.g. the number of times doses need to be taken in a day) and whether or not combined 49 
pills containing different drugs of different characteristics are used.[70, 71] 50 
 51 
We provide two illustrations: not taking any treatment at a given time point versus not taking 52 
some of the drugs. 53 
 54 
When all drugs are omitted at the same time, the implications of longer and shorter breaks 55 
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should be considered separately. Longer gaps from treatment (four days or more) can allow 1 
bacteria to restart replication. It is currently unknown how such an increase in the bacterial 2 
burden may affect treatment outcomes; it may prolong the treatment length required for a 3 
cure. Here, replication after previous exposure to antibiotics may facilitate the emergence of 4 
resistance. 5 
 6 
Shorter breaks (one to two days; Table 1) may be a problem when different drugs within a 7 
combination regimen have different pharmacokinetic properties and therefore some may 8 
take a considerably longer time to clear and/or reach their therapeutic levels when the 9 
regimen is re-started. As a result, drug concentrations after the first dose and at steady state 10 
will differ considerably in some tissues or plasma. For example, Strydom et al. have 11 
illustrated the effects of the slower accumulation of certain drugs in a pharmacokinetics 12 
study on TB patients undergoing lung resection surgery.[72] In the most detailed study of its 13 
kind, the authors demonstrated that drug concentrations after the first dose of a drug differ 14 
from those at steady state - at least in some tissues - for ethambutol (shown in a different 15 
study[73]), pyrazinamide, moxifloxacin, and linezolid. This was not the case for isoniazid, 16 
rifampicin, and kanamycin. More studies of this type will help us understand how TB drugs 17 
accumulate and behave in relevant lesion types. 18 
 19 
During instances when all drugs are omitted at the same time, the drug that clears more 20 
slowly will be still present after others, resulting in effective monotherapy during the gap. 21 
Even with perfect adherence, it is known that there are periods of effective monotherapy 22 
within each day.[72] The impact of such short bouts of monotherapy on the emergence of 23 
resistance is largely unknown. Drugs that require multiple days to reach their steady state 24 
levels may be below their therapeutic ranges for days after treatment resumes. Frequent 25 
short gaps may therefore keep levels below the therapeutic range for a longer period. 26 
Illustrations of how this would impact rifampicin and moxifloxacin levels in the lungs are 27 
presented (Figure 3). 28 
 29 
If FDCs are not used, it is also possible to suboptimally implement specific components of 30 
the regimen. During the continuation phase of treatment, suboptimal implementation of one 31 
drug will lead to monotherapy; the risk of drug resistance posed by monotherapy was 32 
illustrated by one of the first rifampicin trials in 1968.[74, 75] As a result, the current ethical 33 
maximum for monotherapy studies is 14 days.[76]  34 
 35 
Further data in this area are required to better understand how gap lengths, timings and 36 
frequencies of suboptimal implementation carry the most risk for the emergence of 37 
resistance or in prolonging treatments, and how this is influenced by patient-by-patient 38 
variability in pharmacokinetics (e.g. isoniazid acetylator status) and clinical characteristics 39 
known to influence treatment success.[36] 40 
 41 
The relationship between different types of non-adherence 42 
In addition to considering the different types of non-adherence in isolation, the relationships 43 
between them also have important implications for intervention design. For example, an 44 
approximate doubling in the likelihood of discontinuation in the presence of suboptimal 45 
implementation of <80% versus ≥90% during the initiation phase of treatment has been 46 
demonstrated in data from China (Table 1).[9, 12] Early-stage dose-by-dose monitoring data 47 
from DATs could thus be highly valuable at indicating the patients who will later be in need of 48 
additional adherence support. 49 
 50 
Latent tuberculosis 51 
In our consideration of adherence to TB treatment up to this point, our focus has been on TB 52 
disease. Needless to say, the issues raised are equally important for latent tuberculosis 53 
infection (LTBI) and preventive treatment; there is still a need for a standardised taxonomic 54 
framework within which to discuss non-adherence. Unlike for drug sensitive TB disease, 55 
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adherence studies for LTBI need to take into account the different WHO-recommended 1 
regimen lengths and dosing patterns when applying this framework.[77] 2 
 3 
Numerous studies have documented how adherent patients are to LTBI treatment; such 4 
studies have a far greater focus on non-initiation than studies of treatment for TB disease, 5 
given the interest in a) patients declining take proferred treatment or b) not being offered 6 
treatment.[78, 79] Additionally, the nature of LTBI makes treatment completion the marker of 7 
choice for treatment success by National TB Programmes, thus the proportion of patients 8 
completing treatment has been extensively reviewed.[78-81] For both non-initiation and 9 
discontinuation, levels were highly variable between studies (7-99% and 4-100%, 10 
respectively). A global consensus as to which non-adherence patterns can be safely 11 
tolerated for LTBI regimens of different lengths is urgently needed. As with TB disease, this 12 
should also influence the design of interventions to promote adherence, as well as decisions 13 
on which regimens will be most effective in a given population group (balancing cost; the 14 
length of the regimen, its adverse event profile and the implications for adherence; and 15 
regimen efficacy). 16 
 17 
  18 
Conclusion 19 
As a global TB community, we find ourselves at a crossroads when it comes to treatment 20 
adherence. Through DATs, remote dose-by-dose treatment monitoring has become 21 
accessible like never before, and we have a substantial opportunity to deploy precision 22 
medicine approaches to develop and target adherence-promoting interventions. In the 23 
COVID-19 era, remote monitoring tools are all the more important for TB control due to the 24 
need to reduce patient contact with healthcare services (and we also note the likely impact 25 
of the disruption of the pandemic on adherence itself). 26 
 27 
Important information is, however, missing. Further studies using tools such as DATs need 28 
to be rapidly undertaken to fill critical gaps in our knowledge where only limited data exist 29 
(Table 2). It is essential that interventions are not adopted at the national scale without 30 
rigorous effectiveness and cost-effectiveness studies, such as that being undertaken by the 31 
ASCENT project across five countries.[82] During adoption, careful programmatic 32 
management is also required to avoid the wasteful parallel development of digital tools to 33 
report and manage DAT data.[83] 34 
 35 
Although we advocate in this paper for non-adherence to be considered as three separate 36 
issues, it is important to note that the underlying causes of each component may be similar 37 
and that each component may be inter-related. Effective interventions (such as those taking 38 
a stepped approach to enhanced treatment support e.g. by more frequent contact with 39 
health systems or resolution of insecure housing, etc.), may work across several 40 
components of non-adherence, but this will not been known unless data are analysed in this 41 
fashion. Trials of different interventions should also seek to separate their impact on the 42 
different components of non-adherence.[13] 43 
 44 
The data that arise from studies such as those we propose will raise crucial questions for the 45 
future of TB control. For example, are levels of particularly problematic adherence issues low 46 
enough globally that it is not necessary to watch patients taking every single dose of their 47 
medication? Or should all patients be observed during the initiation phase, given the 48 
medication burden, higher replicating mycobacterial load, and connection between early 49 
suboptimal adherence and discontinuation, then allowed to self-medicate if no issues are 50 
observed? Can culturally-adapted menus of interventions be developed to address the 51 
common forms of non-adherence for any given setting? Can we build predictive models to 52 
determine which patients are most likely to suffer from which problematic non-adherence 53 
issues? 54 
 55 
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To date, the TB literature has largely treated all missed doses of treatment as equally 1 
problematic and equally common. By harnessing the power of dose-by-dose adherence 2 
data, particularly through DATs, we can determine which patterns of missingness are ‘more 3 
equal than others’ - a finding that could revolutionise our approach to non-adherence. 4 
 5 
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Tables 1 
Table 1. The implications of non-adherence patterns for intervention and regimen 2 
design: worked example from China 3 
In a study of 780 patients from a pragmatic cluster-randomized trial in China of electronic reminders to 4 
improve treatment adherence,[9, 12] data were taken from the control arm of the trial (electronic 5 
reminders set to silent, thus no intervention to promote adherence). Medication monitor boxes 6 
provided granular data as to whether each individual dose was taken (box opening used as a proxy). 7 
Treatment was dosed every other day. All patients initiated treatment within this study. Decision 8 
making as which type of non-adherence should be targeted by interventions will also depend upon the 9 
relative impact of each form of non-adherence on outcomes.[84] 10 
Domain Suboptimal implementation Discontinuation 
Number of participants 
affected 
748/780 (95.9%) of all participants 
suboptimally implemented their 
treatment. 
235/780 (30.1%) of all 
participants discontinued early. 
Number of doses missed 9,487/16,794 (56.4%) missed 
doses were due to suboptimal 
implementation. 
7,307/16,794 (43.5%) missed 
doses were due to early 
discontinuation. 
Patterns displayed The median gap length per patient 
was one dose, with a maximum 
number of gaps per participant of 
24. 176/780 individuals (22.6%) 
had gaps of seven doses (a 
fortnight) or more. Suboptimal 
implementation increased over 
time. 
5.1% of individuals had 
discontinued treatment by the 
end of month two,14.4% by the 
end of month four, 18.2% by the 
end of month five, 36.3% by the 
end of month six (including 
individuals missing only their last 
dose). 
Link between suboptimal 
implementation and 
discontinuation? 
Missed doses in the initiation phase due to suboptimal implementation 
associated with increased risk of discontinuation in the continuation 
phase. 
Implications for 
intervention and regimen 
design 
The causes of large numbers of 
short gaps need to be ascertained 
and addressed by an effective 
intervention. 
Given the burden of 
discontinuation and when it 
occurs, shortened regimens may 
have been helpful in this setting. 
Early stage suboptimal 
implementation could act as an 
indicator of patients who require 
an intervention to prevent 
discontinuation. 
 11 
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Table 2. Summary of knowledge gaps 1 
Area Missing information Impact 
Global burden of different 
types of non-adherence 
A better determination of the 
distribution of non-adherence between 
late/non-initiation, suboptimal 
implementation and discontinuation 
Whether there are substantial 
differences between (and within) 
countries. Who displays each pattern 
Why different patterns are displayed 
Stratification of 
settings/populations on the 
basis of the interventions that 
might be useful, including 
changes to healthcare 
processes and systems 
Intelligent intervention design 
Trials vs. normal 
treatment pathway 
The extent to which non-adherence 
varies between clinical trials and in 
normal care settings 
Aids decision-making 
surrounding the adoption of 
new regimens (operational 
efficacy) 
Suboptimal 
implementation patterns 
Improved estimates of the frequency 
and types of suboptimal 
implementation, explicitly excluding 
doses missed due to discontinuation 
Variability in patterns between settings 
and patients 
Causes of these patterns 
Stratification of settings (e.g. 
by healthcare 
system)/populations (e.g. by 
patient characteristics) on the 
basis of the interventions that 
might be useful 
Intelligent intervention design 
Relationship between the 
different components of 
adherence 
Whether early-stage indicators of non-
adherence can predict later issues 
with non-adherence 
Inform clinicians as to which 
non-adherence patterns 
should trigger active 
intervention 
Relationship between 
patterns and patient 
outcomes 
Specific mapping of how different non-
adherence types and patterns impact 
treatment failure (and the need to 
restart treatment) and the 
development of drug resistance, in 
order to prioritise cost-effective 
intervention development and roll-out 
Stratification of 
settings/populations on the 
basis of the interventions that 
might be useful and when 
they should be ‘stepped up’ 
Intelligent intervention design 
Inform clinicians as to which 
non-adherence patterns 
should trigger active 
intervention 
Regimen forgiveness The impact of the commonly displayed 
adherence patterns on forgiveness 
The implications of non-adherence to 
each drug within the multidrug 
regimen 
Inform regimen design 
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Figure legends 1 
Figure 1. The different components of non-adherence to treatment 2 
Using the standard taxonomy described by Vrijens et al.,[14] it is possible to distinguish between the 3 
first and last prescribed doses of medication and the first and last doses taken. In terms of sources of 4 
non-adherence- panel a)- firstly individuals may initiate treatment later than agreed with their clinician. 5 
Secondly, treatment may be discontinued early i.e. before the last prescribed dose. Persistence is the 6 
period between initiation and discontinuation. Thirdly- panel b)- non-adherence arises from how 7 
individuals implement their medication; doses may be missed intermittently. In this diagram, the 8 
complete regimen is only 10 doses. Adapted from Vrijens et al.[14] Panel c) illustrates the impact of 9 
discontinuation within an illustrated population of eight patients taking six doses of treatment each 10 
before treatment is stopped. 38% (1 - 3) discontinue their treatment early, all at different time points. 11 
75% of patients (3-8) display some form of suboptimal implementation. Despite this, doses missed 12 
due to discontinuation make up half of non-adherence across the entire patient population. Panel d) 13 
illustrates different types of suboptimal implementation. Patient 1- short, irregular, gaps. Patient 2- 14 
long, irregular, gaps. Patient 3- regular gaps. Treatment is not stopped after the last illustrated dose. 15 
Green- dose taken, white- missed due to suboptimal implementation, orange- missed due to 16 
discontinuation. 17 
 18 
Figure 2. Cascade of care until the start of tuberculosis treatment 19 
*These two time points may be on the same day. †For drug resistant tuberculosis patients, drug 20 
sensitivity testing results may not be available until after treatment for drug sensitive disease is 21 
initiated, necessitating a chance in regimen. 22 
 23 
Figure 3. Different patterns in suboptimal implementation lead to divergent results. 24 
Rifampicin (red, 600mg dose) and moxifloxacin (black, 400mg dose) concentrations were modelled in 25 
uninvolved lung tissues. This combination is currently being investigated in clinical trials,[85] but the 26 
two drugs have very different pharmacokinetic properties. The three different plots show the same 27 
suboptimal implementation patterns as Figure 1d). Patient 1- short, irregular gaps. Patient 2- long, 28 
irregular gaps. Patient 3- regular gaps. The different shaded areas indicate different issues with drug 29 
concentrations. Cream indicates periods where only moxifloxacin is above the minimum inhibitory 30 
concentration (MIC). Above the MIC the drug either stops replication completely or eliminates 31 
bacteria, therefore during these periods there is an effective moxifloxacin monotherapy. Grey areas 32 
are periods where no drug is above the MIC; as a result, bacteria may eventually restart replication. 33 
Dark blue periods are when moxifloxacin concentrations do not reach the levels (therapeutic range) 34 
expected during proper adherence. In these cases, bacterial elimination rates for the given period 35 
may be lower than expected, therefore possibly delaying the time it takes to clear bacteria.  The 36 
presented MIC cut-offs are mainly for illustration purposes, to indicate time periods where adverse 37 
events may occur due to differences in concentrations, rather than capturing events on a bacterial 38 
population level. Bacterial population dynamics are governed by multiple factors in addition to drug 39 
concentrations e.g. the post-antibiotic effect. For instance, growth rates of bacteria may be affected by 40 
the post-antibiotic effect.[86] Furthermore, selection of resistance mechanisms also occurs at sub-41 
MIC concentrations.[87] The plots were made with the model and parameters published by Strydom 42 
et al.[72]  43 
